Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance

被引:34
|
作者
Mazumder, Sonia [1 ]
Higgins, Paul J. [1 ]
Samarakoon, Rohan [1 ]
机构
[1] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA
关键词
ccRCC; HIF-alpha; VHL; EGFR; MET; HYPOXIA-INDUCIBLE FACTOR; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TYPE-1; MATRIX-METALLOPROTEINASE; CLINICAL-PRACTICE GUIDELINES; VONHIPPEL-LINDAU DISEASE; CYCLIN D1 EXPRESSION; C-MYC; INTERFERON-ALPHA; FACTOR RECEPTOR;
D O I
10.3390/cancers15041316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clear cell variant of renal cell carcinoma (ccRCC) is the most common renal epithelial malignancy and responsible for most of the deaths from kidney cancer. Patients carrying inactivating mutations in the Von Hippel-Lindau (VHL) gene have an increased proclivity to develop several types of tumors including ccRCC. Normally, the Hypoxia Inducible Factor alpha (HIF-alpha) subunits of the HIF heterodimeric transcription factor complex are regulated by oxygen-dependent prolylhydroxylation, VHL-mediated ubiquitination and proteasomal degradation. Loss of pVHL function results in elevated levels of HIF-alpha due to increased stability, leading to RCC progression. While HIF-1 alpha acts as a tumor suppressor, HIF-2 alpha promotes oncogenic potential by driving tumor progression and metastasis through activation of hypoxia-sensitive signaling pathways and overexpression of HIF-2 alpha target genes. One strategy to suppress ccRCC aggressiveness is directed at inhibition of HIF-2 alpha and the associated molecular pathways leading to cell proliferation, angiogenesis, and metastasis. Indeed, clinical and pre-clinical data demonstrated the effectiveness of HIF-2 alpha targeted therapy in attenuating ccRCC progression. This review focuses on the signaling pathways and the involved genes (cyclin D, c-Myc, VEGF-a, EGFR, TGF-alpha, GLUT-1) that confer oncogenic potential downstream of the VHL-HIF-2 alpha signaling axis in ccRCC. Discussed as well are current treatment options (including receptor tyrosine kinase inhibitors such as sunitinib), the medical challenges (high prevalence of metastasis at the time of diagnosis, refractory nature of advanced disease to current treatment options), scientific challenges and future directions.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] The VHL/HIF axis in clear cell renal carcinoma
    Shen, Chuan
    Kaelin, William G., Jr.
    SEMINARS IN CANCER BIOLOGY, 2013, 23 (01) : 18 - 25
  • [2] HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
    Gordan, John D.
    Lal, Priti
    Dondeti, Vijay R.
    Letrero, Richard
    Parekh, Krishna N.
    Oquendo, C. Elisa
    Greenberg, Roger A.
    Flaherty, Keith T.
    Rathmell, W. Kimryn
    Keith, Brian
    Simon, M. Celeste
    Nathanson, Katherine L.
    CANCER CELL, 2008, 14 (06) : 435 - 446
  • [3] TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling
    Zhang, Xinchao
    Li, Shuyan
    He, Jing
    Jin, Yunjie
    Zhang, Ruonan
    Dong, Wenjing
    Lin, Mingen
    Yang, Yajing
    Tian, Tongguan
    Zhou, Yuefan
    Xu, Yixin
    Lei, Qun-Ying
    Zhang, Jing
    Zhang, Qing
    Xu, Yanping
    Lv, Lei
    CANCER RESEARCH, 2022, 82 (11) : 2097 - 2109
  • [4] IDENTIFICATION OF NOVEL HIF INDEPENDENT ONCOGENIC TARGETS IN CLEAR CELL RENAL CELL CARCINOMA
    Scovell, Jason M.
    Zayas, Shannon
    Grubb, Treg
    Abhishek, Chakraborty
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1065 - E1066
  • [5] VHL inactivation in sporadic clear cell renal carcinoma
    Mikhaylenko, D. S.
    Kurynin, R. V.
    Popov, A. M.
    Karyakin, O. B.
    Enikeev, M. E.
    Alyaev, Yu. G.
    Nemtsova, M. V.
    Zaletayev, D. V.
    MOLECULAR BIOLOGY, 2008, 42 (01) : 64 - 69
  • [6] VHL inactivation in sporadic clear cell renal carcinoma
    D. S. Mikhaylenko
    R. V. Kurynin
    A. M. Popov
    O. B. Karyakin
    M. E. Enikeev
    Yu. G. Alyaev
    M. V. Nemtsova
    D. V. Zaletayev
    Molecular Biology, 2008, 42 : 64 - 69
  • [7] Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma
    Sourbier, Carole
    Srivastava, Gaurav
    Ghosh, Manik C.
    Ghosh, Sanchari
    Yang, Youfeng
    Gupta, Gopal
    DeGraff, William
    Krishna, Murali C.
    Mitchell, James B.
    Rouault, Tracey A.
    Linehan, W. Marston
    ONCOTARGET, 2012, 3 (11) : 1472 - 1482
  • [8] Novel biomarkers and therapeutic targets in clear cell renal cell carcinoma (ccRCC)
    Meseguer Navarro, Anna
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 17 - 18
  • [9] VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
    Athina Ganner
    Christina Gehrke
    Marinella Klein
    Lena Thegtmeier
    Tanja Matulenski
    Laura Wingendorf
    Lu Wang
    Felicitas Pilz
    Lars Greidl
    Lisa Meid
    Fruzsina Kotsis
    Gerd Walz
    Ian J. Frew
    Elke Neumann-Haefelin
    Scientific Reports, 11
  • [10] VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
    Ganner, Athina
    Gehrke, Christina
    Klein, Marinella
    Thegtmeier, Lena
    Matulenski, Tanja
    Wingendorf, Laura
    Wang, Lu
    Pilz, Felicitas
    Greidl, Lars
    Meid, Lisa
    Kotsis, Fruzsina
    Walz, Gerd
    Frew, Ian J.
    Neumann-Haefelin, Elke
    SCIENTIFIC REPORTS, 2021, 11 (01)